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Cancer is now the second leading cause of death in the developed world and accounts 
for 1 out of every 4 deaths in the US (American Cancer Society).  The fundamental defect of 
cancer is unregulated cell division.  One way this can happen is from an increase in the 
activity of proteins which signal cell growth.  These proteins, called proto-oncogenes, 
possess normal functions in cells but can induce unregulated cell division when permanently 
activated by mutation.  Understanding the molecular biology behind proto-oncogenes may 
lead to insight into how cancer develops and aid in the development of better treatment 
options for cancer patients.  We are interested in studying Bright, a proto-oncogene expressed 
in mouse B-cells, white blood cells which are an essential part of the immune system.  Bright 
can induce proliferation when overexpressed in normal cells.  Our ultimate goal is to 
understand the mechanism by which Bright causes cells to become cancer-like.   
Bright’s oncogenic activity is correlated with an increase in function of E2F1, a 
protein considered to be a master regulator of cell division.  E2F1 controls the transcription 
of many genes needed to drive the cell cycle.  Specifically, we are interested in understanding 
how Bright upregulates the ability of E2F1 to activate transcription of its target genes.  
Various lines of evidence suggest that Bright may disrupt the action of pRb/E2F1 complexes 
which normally repress E2F1 production at the E2F1 promoter.  Several biological studies 
have been performed to investigate this possibility and to learn more about the action of 
Bright.  In our first experiment, we determine which properties of Bright are necessary to 
transform cells.  Second, we show that Bright can associate with pRb, suggesting that Bright 
may play a role in E2F1 regulation.  Finally, chromatin immunoprecipitation assays suggest 
that Bright associates with the E2F1 promoter and may indeed affect the function of 
pRb/E2F1 repressive complexes.  Thus, we provide evidence in support of a novel model for 
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Bright’s oncogenic properties.  Our findings are particularly relevant for patients with 
Activated B cell-like Diffuse Large B-cell Lymphoma, a highly pernicious cancer that 
appears to involve the human version of Bright.  Further studies to explore the nature of 
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Background 
As cancer now becomes one of the leading causes of death in the developed world, 
research aimed at understanding the mechanism of cancer formation is becoming especially 
important.  The work presented in this thesis is part of an ongoing project to understand what 
makes Bright, a transcription factor expressed in B-cells, a proto-oncogene.  Proto-oncogenes 
are proteins which can induce unregulated cell division when they are overexpressed or 
permanently activated by mutation (reviewed in Darnell, 2002).  In light of previous work, it 
is apparent that our simple question has a relatively complex answer.  Peeper et al (2002) 
found that hDril1, the human orthologue of Bright, can cause uncontrolled cell division, a 
molecular hallmark of cancer, by interfering with an important tumor suppressor pathway.  
Does Bright itself possess the same oncogenic properties as hDril1?  If so, what specific 
component(s) of the tumor suppressor pathway does Bright interfere with?  These are our 
specific questions of interest.  To address the first question, we have conducted senescence 
rescue assays to test if Bright indeed has oncogenic activity.  To address the second question, 
we examine Bright’s interaction with E2F1, a downstream target of the tumor suppressor 
pathway and an important transcription factor controlling G1/S cell cycle progression 
(reviewed in Dyson, 1998).  Our results suggest that Bright is a proto-oncogene, like hDril1, 
and transforms cells by de-repressing E2F1.   
 The goal of this background section is to highlight concepts relevant to the story of 
Bright.  The first two sections provide a summary of basic cancer biology and Ras induced 
senescence.  These concepts are foundational to the experiments presented in the results 
section.  The third and fourth sections introduce our protein of interest, Bright, and 
characterize the oncogenic properties of hDril1, the human version of Bright.  Finally, the 
last section describes the mechanism of E2F1 regulation.   
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Cell Malignancy 
Cancer, or uncontrolled cell proliferation, is essentially a disease of genetic mutation.  
Alterations in the sequence of genes can disrupt complex signaling pathways designed to 
regulate when a cell grows or divides (reviewed in Vogelstein and Kinzler, 2004; Hahn and 
Weinberg, 2002). The growth of cells is normally tightly regulated.  In fact, almost all diploid 
mammalian cells are “programmed” to have a specific life span (Hayflick, 1995).  Human 
embryo fibroblast cells can only live for 50-60 population doublings before undergoing 
natural growth arrest, or senescence.  Essentially, senescent cells are “stuck” in the G0 phase 
of the cell cycle.  Cessation of cell division is a natural phenomena caused by a number of 
factors including DNA damage, oxidative stress, increased activity of growth-suppressing 
proteins and telomere shortening (Serrano and Blasco, 2001).  However, it is also possible for 
cells to become senescent through aberrant expression of oncogenic proteins.  This process is 
highly abnormal and often is the basis for cancer formation.  One way this can happen is 
through an activating mutation in a proto-oncogene, such as Ras or Myc (Campisi, 2001).  
Since proto-oncogenes normally function to promote cell growth, they are typically activators 
of cell division, pro-growth signaling molecules and transcription factors (Evan et al, 2001).  
An activating mutation in a proto-oncogene results in constitutive pro-growth signaling in the 
cell.  These signals drive cell cycle progression and result in unregulated cell division.  
However, cells have developed a strategy to control inappropriate pro-growth signals.  Tumor 
suppressor genes serve to slow down cell cycle progression.  Since tumor suppressor genes 
possess anti-proliferation activity, they usually encode for regulators of the cell cycle, signals 
for DNA damage repair or inducers of normal cell death, called apoptosis (Evan et al, 2001).  
If both diploid copies of a proto-oncogene become activated and tumor suppressor genes lose 
function, cell growth becomes unregulated.  A once normal eukaryotic cell will now 
transform into a cancer-like cell.  Instead of undergoing senescence, transformed cells 
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become immortal and show decreased requirements for growth signals, resistance to 
apoptosis and loss of cell cycle control (Hanahan and Weinberg, 2000).  The relationship 
between tumor suppressor genes and proto-oncogenes may become clearer by drawing an 
analogy to parts of a car.  Tumor suppressor genes are analogous to the brakes, acting to slow 
down cell growth while proto-oncogenes are analogous to the gas-pedal, acting to speed up 
cell growth.  When both the brakes stop working (inactivation of tumor suppressor genes) 
and the gas-pedal is stuck down (activation of proto-oncogenes), the car cannot be controlled 
(unregulated cell division).   
 It is now generally believed that cancer arises from multiple mutations in the cell.  
These mutations affect tumor suppressor genes and proto-oncogenes.  This idea was first 
proposed by Carl Nordling in 1953 and then extended by Alfred Knudson in 1971.  Knudson 
showed that the occurrence of retinoblastoma resulted from two independent mutations, each 
affecting one of the two retinoblastoma alleles (Knudson, 1971).  Currently, the paradigm in 
cancer biology is that mutations in tumor suppressor genes and proto-oncogenes are both 
needed for cancer formation.  Accordingly, a good way to test for oncogenic properties is to 
co-express a protein of interest with another known oncogene (assuming the protein of 
interest is suspected to affect the tumor suppressor pathway).  This simulates two mutations 
in a cell: activation of an oncogene and inactivation of the tumor suppressor pathway.  This is 
the theory behind “BTR cells”, the model cell line which we use to study Bright.   
 
RasV12 induced senescence 
Normally, the growth and proliferation of cells is tightly controlled by complex 
signaling pathways.  The cell growth signal pathway begins with plasma membrane receptors 
binding growth factors outside the cell (Howe et al, 1998).  Receptors which have bound 
growth factor become activated and trigger intracellular signal cascades.  These signal 
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cascades ultimately activate transcription factors, which facilitate expression of genes 
promoting cell cycle progression.  The cell then proceeds to complete cell division.   Because 
these signaling pathways “tell” cells when to divide, an activating mutation of any one 
component(s) can result in unregulated cell proliferation. 
Ras, a family of pro-growth signaling molecules, is particularly relevant to this thesis.  
Ras genes encode for small G-proteins, important signal transducing molecules which 
interact with plasma membrane receptors (Downward, 2003).  Constitutively active Ras 
(formed by mutation) will continually transmit pro-growth signals.  About 20% of all human 
tumors have a mutation in one of the alleles for Ras (Downward, 2003).  In these tumors, 
downstream signaling by Ras contributes to the observed phenotype, including deregulation 
of cell growth, resistance to programmed cell death, and the ability to induce new blood-
vessel formation (Shields et al, 2000).   
In primary cells, oncogenic RasV12, a constitutively active Ras, induces senescence 
via the p53/pRb tumor suppressor pathways (Sherr and Weber, 2000).  Recall that this is an 
example of an activated oncogene (RasV12) triggering a tumor suppressor pathway (p53/pRb) 
to control pro-growth signals.  Interestingly, mouse embryonic fibroblasts (MEFs) from p53 
knockout mice fail to undergo senescence and can be transformed by RasV12 only, suggesting 
that this tumor suppressor pathway is responsible for senescence activation.  A closer look is 
required to understand exactly how senescence in achieved (Figure 1).  RasV12 expression 
results in an induction of two tumor suppressors p19ARF and p16Ink4a (Serrano et al, 1997).  
p19ARF stabilizes p53 by promoting degradation of the p53 ubiquitin ligase, MDM2.  
Increased levels of p53 promote cell cycle arrest and activation of various inhibitors of Cdks, 
protein complexes which promote cell cycle progression.  p16INK4a halts cell cycle 
progression by blocking pRb repression of E2F, a family of transcription factors promoting 
G1/S cell cycle progression.  Interestingly, pRb can induce cell cycle arrest in p53 deficient 
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cells, suggesting that pRb may act downstream of p53 (Alexander and Hinds, 2001).  
Additionally, Rowland et al (2002) showed that E2F repressor complexes are downstream 
targets of p19ARF/p53 senescence.  Together, these observations indicate that the p53 and pRb 
pathways may converge on E2F (Sebastian et al, 2005). 
 
Bright 
Our protein of interest is Bright (B-cell regulator of immunoglobulin heavy chain 
transcription; also known as Arid3a), a 70-kDa protein expressed in mouse B-cells.  Bright 
was first discovered as a member of a protein complex binding to regulatory DNA (Webb et 
al., 1991; Herrscher et al., 1995).  It is now known that Bright can upregulate transcription of 
the immunoglobulin heavy chain (IgH) in mature B-cell lines (Herrscher et al., 1995; Wang 
et al., 1999).  Bright contains a DNA binding domain (ARID, or A-T rich interacting 
Figure 1: Tumor suppressor response to activated RAS. 
Activation of oncogenic RAS causes induction of p19ARF and p16Ink4a.  p19ARF blocks 
the activity of MDM2, resulting in activation of p53.  p16Ink4a blocks cyclin dependent 
kinases from phosphorylating pRb.  This “fail-safe” response can result in cellular 
apoptosis or senescence.  (Borrowed from Schmitt, 2003). 
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domain), a trans-activation domain and a multimerization domain (REKLES domain).  The 
ARID DNA-binding domain mediates Bright binding to A-T rich sequences on specific 
immunoglobulin heavy chain regulatory DNA (Herrscher et al, 1995).  It is in this manner 
that Bright activates IgH transcription.  The REKLES domain is required for Bright nuclear 
import/export and is important in regulating the multimerization of Bright as a homo-tetramer 
or hetero-tetramer with its paralogue Bdp (Kim et al, 2006; Kim et al, 2007).  Additionally, 
Bright undergoes a cell-cycle dependent shuttling event between the nucleus and cytoplasm 
(Kim and Tucker, 2006).  This shuttling event is essential to Bright’s activity.  Bright is also 
post-transcriptionally modified by SUMO (small ubiquitin-related modifier).  SUMO is a 
covalently attached protein modifier which has been shown to alter protein localization 
(Friedlander and Melchior, 2007). 
 
Human version of Bright is a proto-oncogene  
As explained above, activated RasV12 triggers the pRb/p53 tumor suppressor pathways to 
induce senescence.  Therefore, genes which can rescue, or overcome, RasV12 induced 
senescence must have oncogenic properties.  Peeper et al (2002) conducted a retroviral 
complementary DNA screen in an effort to identify genes that could rescue RasV12 induced 
senescence in mouse embryonic fibroblasts (MEFs).  To reduce background in the screen, 
Peeper et al (2002) created a unique cell line, called BTR (Figure 2).  These cells are also 
used in our study of Bright.  BTR cells express both activated RasV12 and a temperature-
sensitive mutant of the simian virus 40 (SV40) Large T antigen, which can induce continuous 
cell proliferation (Lee et al, 1995).  At the permissive temperature (32°), cells rapidly 
proliferate since the SV40 Large T antigen is active, allowing escape from RasV12 induced 
senescence.  At the non-permissive temperature (39.5°), cells undergo premature senescence 
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since the SV40 Large T antigen is inactive.  Peeper et al found that hDril1, the human 
orthologue of Bright, can bypass RasV12 senescence at the non-permissive temperature 
(Figure 3).  In fact, hDril1 allows escape from spontaneous senescence in MEFs and can 
induce tumor formation in nude mice (Peeper et al, 2002).  These observations suggest that 
hDril1 must be interfering with the growth-arrest signals produced by the pRb/p53 tumor 
suppressor pathways.  Peeper et al conducted additional experiments to identify what 
components of the pathway were being disrupted by hDril1.  As expected, RasV12 expression 
led to an induction of p19ARF, p16INK4a and p53.  However, co-expression of RasV12 and 
hDril1 did not interfere with the level of these tumor suppressors as compared to RasV12 
expression alone.  Thus, it is suggested that hDril1 rescues senescence downstream or 
independent of p19ARF, p16INK4a and p53.  The second important result by Peeper et al is that 
hDril1 senescence rescue is correlated with an induction of CYCLIN E, an important cell 
Figure 2: The BTR cell system. 
At the permissive temperature (32°C) the SV40 Large T antigen is active, causing BTR 
cells to proliferate.  At the non-permissive temperature (39.5°C) the SV40 Large T 
antigen is inactive, causing BTR cells to become senescent due to RASV12 expression.  
(Borrowed from Peeper et al, 2002). 
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cycle regulator which shuts off pRb by activating its hyperphosphorylation by Cdc2.  
Overexpression of CYCLIN E is sufficient to allow escape from senescence.  Additionally, 
the CYCLIN E promoter is controlled by the transcription factor E2F1.  Therefore, hDril1 
may interfere with the tumor suppressor pathway at the level of pRb-E2F1.  We investigate 
this possibility in the results section. 
 
E2F1, pRb and cell cycle regulation: 
The balance of positive and negative growth regulatory signals in cells ultimately acts on the 
E2F transcription factor family, referred to as the “master regulators” of the cell cycle.  E2F 
Figure 3: Human Bright, hDril1, can transform senescent cells. 
Primary MEFs were retrovirally infected with RasV12 or co-infected with RasV12 and 
hDril1.  As the proliferation curves indicate, hDril1 can transform RasV12-senescent cells.  
(Figure borrowed from Peeper et al, 2002). 
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controls the transcription of many genes needed to drive the cell cycle, including cell cycle 
regulators (i.e. cyclins, Cdc2, pRb), enzymes needed in nucleotide production (dihydrofolate 
reductase, thymidine kinase) and components needed for DNA replication (ORC1) 
(Trimarchi and Lees, 2002).  David Johnson and co-workers found that overexpression of 
E2F1 complementary DNA was sufficient to activate DNA synthesis in cells that would have 
undergone growth-arrest (Johnson et al, 1993).  Thus, overexpression of E2F1 allows G1/S 
phase transition.  This finding has been supported by other studies (Shan and Lee, 1994; 
Kowalik et al, 1995).  Furthermore, in vivo studies have shown that E2F1 overexpressing 
mice in conjunction with Ras expression can induce tumor development in mice (Pierce et al, 
1998).  
The model for E2F1 regulation is of particular relevance to this thesis (Figure 4).  
Figure 4: Mechanism of E2F1 regulation by pRb 
During early G1, pRb is hypophosphorylated and complexes with E2F1-DP.  The 
pRb/E2F1-DP complex then associates with the E2F1 promoter and recruits class I 
histone deacetylase (HDAC1) which repress transcription.  When the cell receives pro-
growth signals, cyclin dependent kinases become active and phosphorylate pRb.  This 
releases E2F1-DP allowing it to activate transcription.  (Adapted from Trimarchi and 
Lees, 2002). 
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Many studies have made it clear that E2F1 is the target of pRb repression (Hamel et al, 1992; 
Weintraub et al, 1992; Sellers et al, 1995).  The phosphorylation state of pRb determines the 
activity level of E2F1.  During growth-arrest or early G1, pRb is hypophosphorylated and 
forms a complex with E2F1-DP, the functional heterodimer of E2F1.  This complex binds to 
and inhibits transcription of E2F1-controlled genes.  The mechanism of this transcriptional 
repression has been studied extensively.  It is suggested that the pRb/E2F1-DP complex binds 
to the promoter of E2F1-controlled genes and recruits class I histone deacetylase proteins 
(HDAC1).  HDAC1 represses transcription by removing acetyl groups from histones 
resulting in the condensation of chromatin and therefore, blocked binding of transcription 
factors.  When the cell is growing, pRb becomes hyperphosphorylated by cyclin-dependent 
kinases and releases E2F1-DP.  CYCLIN E is a member of one of these cyclin-dependent 
kinases.  E2F1-DP can then activate transcription of genes needed for G1/S cell cycle 
progression.  Understanding the model of pRb-E2F1 repression is imperative to 




There were three main aims addressed in this thesis: 
(1) Determine which properties of Bright are necessary for transformation of cells. 
(2) Examine the nature of Bright’s interaction with pRb. 
(3) Determine if Bright is localized at the E2F1 promoter. 
  
Both wild-type Bright and a sumoylation defective mutant can rescue senescence:   
In the first section of this project, we investigated which properties of Bright are 
necessary for its oncogenic activity.  Peeper et al (2002) described the RasV12 senescence 
rescue ability of hdril1, the human orthologue of Bright.  Unpublished data in the Tucker lab 
has shown that Bright can rescue RasV12 senescence in a manner similar to hdril1 (i.e. 
downstream of p53/p19ARF, correlated with induction of E2F1 and CYCLIN E).  We 
Figure 5: Schematic of Bright indicating positions of substitution mutations. 
Bright point mutants were obtained from Kim and Tucker (2006).  K466A is cytoplasm 
restricted. G532A is nucleus restricted.  401KIKK/AIAA is a sumoylation defective 
mutant.  W299A/Y330A is a true dominant negative form of Bright.  C342S and C342D 
are conservative and non-conservative point mutants of the single conserved cysteine 
residue in the ARID domain, respectively.
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examined the senescence-rescue ability of five Bright point-mutants made by Kim and 
Tucker (2006) (Figure 5). The mutant K466A contains a defective nuclear localization 
sequence and is therefore only present in the cytoplasm.  G532A is a nuclear export sequence 
point mutant and is nucleus restricted.  401KIKK/AIAA is unable to be post-transcriptionally 
modified by the addition of a sumoylation tag.  C342S and C342D are conservative and non-
conservative substitution mutants for the single conserved cysteine residue in the ARID DNA 
binding domain.  C342 mutation does not interfere with DNA binding or transactivational 
properties of Bright (Schmidt et al, 2009). 
The vector pVxy was used to construct retroviruses containing wild-type and mutant 
forms of Bright.   Mouse embryonic fibroblasts were infected at passage 3.  Two days after 
Figure 6: Mouse embryonic fibroblasts are rescued from senescence by Bright and 
the Bright sumoylation defective mutant 401KIKK/AIAA. 
Primary MEFs were infected with the indicated forms of Bright.  Trypan blue negative 
cells were counted.  MEFs infected with wild-type Bright and the sumoylation-defective 
mutant 401KIKK/AIAA show rapid cell proliferation beyond the normal senescence point 
of these cells, at passage 3. 
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infection, cells were grown in the presence of puromycine and the number of trypan blue 
cells was counted.  Our results indicate that only wild-type Bright and the sumoylation 
defective mutant 401KIKK/AIAA can rescue RasV12 induced senescence in MEFs (Figure 6).  
This is supported by significantly higher numbers of viable cells counted at day 11 for wild-
type Bright and 401KIKK/AIAA compared to the other Bright mutants tested (G532A, 
K466A, C342S and C342D).  The empty vector culture shows extremely low levels of trypan 
blue-included cells, indicating a low amount of background.  Expression of Bright was 
consistent in all mutant cell lines as indicated by the western blot.  The sumoylation defective 
mutant, 401KIKK/AIAA, appears to induce cell proliferation earlier than wild-type Bright as 
indicated by higher levels of trypan blue inclusion at day 9 for 401KIKK/AIAA compared to 
wild-type Bright.   
To confirm our results, we stained for senescence associated β-galactosidase activity 
of BTR cells infected with wild-type and mutant forms of Bright.  BTR cells were first grown 
at the permissive temperature (32°).  After two days, cells were shifted to the non-permissive 
temperature (39.5°) resulting in the inactivation of the SV40 Large T antigen.  Senescence 
was measured by staining cells at acidic pH for β-galactosidase activity (Dimri et al. 1995).  
Viable cells were measured by their ability to counterstain with Eosin.  This results in blue 
colonies, which are senescent, and red colonies, which are actively proliferating.  In 
agreement with our earlier results, wild-type Bright and the sumoylation defective mutant 
401KIKK/AIAA rescued RasV12 senescence at the non-permissive temperature (Figure 7).  The 
lack of contact inhibition (ie, cell density) observed in both cultures suggests that these 
senescent fibroblasts have undergone transformation, although this conclusion has formally 
not been confirmed.  The empty vector culture served as a negative control and did not rescue 
senescence.  The cysteine mutants, C342S and C342D, also did not rescue senescence.  This 
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suggests that Bright’s conserved cysteine in the ARID domain confers a property necessary 





Figure 7: Wild-type Bright and 401KIKK/AIAA can rescue RASV12-induced 
senescence in BTR cells.  
BTR cells were infected with retroviruses encoding the indicated forms of Bright.  Cells 
were grown at the permissive temperature (32 ºC) for three days followed by a shift to the 
non-permissive temperature (39.5 ºC) for ten days.  Cultures were stained for senescence-
associated β-galactosidase activity and counterstained with eosin.  Photographs of the 
individual plates are shown.  Plates for Bright and 401KIKK/AIAA are red indicating 
transformation of RasV12 senescent cells.  All other Bright mutants tested do not rescue 
RasV12 senescence and therefore stain blue. 
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Bright rescuing ability is correlated with hyperphosphorylation of pRb: 
In the second phase of this project, we examined a potential association between Bright and 
pRb.  Bright appears to be involved in pRb-E2F1 regulation based on the results of Peeper et 
al (2002) and unpublished data from the Tucker lab.  Investigating a relationship between 
Bright and pRb may help explain our finding that Bright rescues Ras induced senescence in 
the previous section.  We assayed for pRb levels and phosphorylation status in BTR cells 
containing wild-type and mutant forms of Bright.  Cells were lysed, and then ~50-80 µg of 
Figure 8: Bright/Arid3a senescence rescue is correlated with the hyperphosphorylation of 
pRb.  
Btr cells expressing different Bright/Arid3a point mutants were grown at the permissive 
temperature (32 ºC) for three days followed by a shift to the non-permissive temperature 
(39.5 ºC) for ten days.  Whole cell lysates were prepared and 0.1% of the input was 
probed with antibodies against Bright, Actin and Rb.  Immunoprecipitation of Bright was 
performed using pre-cleared extract and anti-Bright antiserum.  Western analysis indicates 
that wild-type Bright and 401KIKK/AIAA, forms of Bright which can rescue senescence, 
have increased levels of hyperphosphorylated pRb at the non-permissive temperature 
(39.5 ºC).   
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extracted cell proteins were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). The separated proteins were transferred from the gel to a 
nitrocellulose filter and probed using the appropriate antibodies (Figure 8).  To ensure that 
equivalent amounts of extract were loaded onto the SDS-PAGE gel, actin (a ubiquitous 
protein whose levels are not affected by cell cycle alteration) was used as a loading control.  
The pRb antibody used in these experiments recognizes both the hypophosphorylated and the 
hyperphosphorylated forms of pRb.  Hypophosphorylated pRb runs slightly faster on the gel 
than hyperphosphorylated pRb due to differences in charge and conformation.  Input lanes 
show that at the permissive temperature (32°), all BTR cells contain roughly equal levels of 
hyperphosphorylated and hypophosphorylated pRB (if not slightly more hypophosphorylated 
pRb).  However, at the non-permissive temperature (39.5°), BTR cells expressing wild-type 
Bright and 401KIKK/AIAA contain increased levels of the hyperphosphorylated form of pRb.  
Combined with our previous results, this suggests that Bright’s RasV12 senescence rescuing 
ability is correlated with an increase in the level of hyperphosphorylated Bright.   
 
Bright associates with hyperphosphorylated pRb during RasV12 senescence rescue: 
Next, we tested for an association between Bright and pRb.  Bright was 
immunoprecipitated out of BTR cell lysates using α-Bright antibody and product was run on 
a SDS-PAGE gel.  The western blot shows that Bright can be found complexed with pRb 
(Figure 8).  Only wild-type Bright interacts with pRb at the permissive temperature (32°) but 
both wild-type Bright and the 401KIKK/AIAA mutant interact with pRb at the non-permissive 
temperature (39.5°).  Interestingly, none of the other Bright mutants were complexed with 
pRb.  To further test this hypothesis, we examined an additional ARID domain mutant in 
which residues essential to Bright DNA binding (W299 and Y330) had been changed.  Under 
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conditions in which better resolution of the bands were achieved (Figure 9), we observed 
clearly that wild-type Bright is predominately complexed with hypophosphorylated pRb at 
32° and hyperphosphorylated pRb at 39.5°.  Collectively, our results indicate that Bright’s 
association with pRb may be necessary for its function as a proto-oncogene.  Since these 
immunoprecipitation assays cannot verify direct protein-protein interaction, we cannot 
distinguish whether Bright directly binds to pRb or binds through association of an additional 




Figure 9: Bright/Arid3a is complexed with hyperphophorylated pRb during senescence 
rescue. 
Western analysis indicates that wild-type Bright is predominantly complexed with 
hyperphosphorylated pRb at the non-permissive temperature (39.5 ºC).  In immortal BTR 
cells, wild-type Bright is complexed with hypophorphorylated pRb.  W299A/Y330A, the 
dominant negative Bright mutant, cannot be found complexed with pRb. 
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Bright is recruited to the E2F1 promoter in BTR cells: 
There are several lines of evidence that suggest that Bright may be involved in E2F1 
regulation.  Peeper et al (2002) found that hDril1 rescues RasV12 senescence downstream of 
p53/p19ARF, implying that hDril1 may bypass the tumor suppressor pathway at the level of 
E2F1.   Second, it has been shown that hDril1 can interact with E2F1 (Suzuki et al, 1998).  
Also, unpublished data in the Tucker lab shows that Bright is complexed with both E2F1 and 
pRb.  To address the third aim of this project, we investigated a possible association between 
Bright and the E2F1 promoter.   
To understand the results of these experiments, it is important to revisit the model of 
E2F1 gene regulation described in the background section.  During senescence (G0/G1 of the 
cell cycle), hypophosphorylated pRb forms a complex with E2F1-DP, the functional 
heterodimer of E2F1.  This complex binds to the promoter of E2F1 and recruits class I 
histone deacetylase proteins (HDAC1), which repress transcription.  When the cell begins to 
divide (S phase of the cell cycle), pRb becomes hyperphosphorylated by cyclin-dependent 
kinases and releases E2F1-DP.  E2F1-DP can then activate transcription of E2F1 (Johnson et 
al, 1994).  The results of Peeper et al (2002) imply that hdril1 may be directly involved in 
E2F1 transcription regulation by pRb.  Since Bright can be complexed with pRb and can bind 
to E2F1, we hypothesized that Bright may be recruited to the promoter of E2F1.  This could 
help explain the observation that Bright induces E2F1 transcription function.  Therefore, we 
assayed for the presence of Bright on the E2F1 promoter region using a molecular biologic 
technique called chromatin immunoprecipitation (ChIP).   
ChIP is used to determine if a protein of interest is localized to a specific region of 
DNA in the living cell.  Cells are first treated with formaldehyde to cross-link DNA binding 
proteins to chromatin.  Following cross-linking, cells are lysed and DNA is sheared through 
sonication.  Protein-DNA complexes are immunoprecipitated using an antibody against the 
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protein of interest.  A sample of this product is run on a SDS-PAGE gel and analyzed by 
Western blot.  The remaining sample is reversed cross-linked and treated with proteinase K 
to degrade all proteins.  The DNA is purified and identified by using polymerase chain 
reaction (PCR).  For the PCR, three primer pairs were designed, two spanning regions 
outside the E2F1 binding site within the E2F1 promoter region (serving as negative controls), 
and one spanning the promoter region itself (Figure 10).  Primer sequences can be found in 
the Methods section.   
 
The first step was to optimize conditions for the ChIP procedure based on our cell 
line and PCR primers of choice.  We established sonication conditions to shear cross-linked 
DNA to 200-1000 base pairs in length in BTR cells.  Additionally, we established PCR 
conditions to enhance specificity of E2F1 promoter DNA amplification.  We confirmed our 
ChIP optimization by assaying for an association between Bright and purified DNA from 
Bright overexpressing NIH/3T3 cell lysates (data not shown).  Following cross-linking and 
sonication, protein-DNA complexes were immunoprecipitated using anti-Bright antibody.  
Western analysis of this sample indicated the presence of Bright.  After reverse cross-linking 
Figure 10: Diagram of ChIP primer landing regions. 
Primer pair 1 spans the E2F1 promoter.  Primer pair 3 is far upstream and primer pair 2 is 
located within the E2F1 coding segments (serving as negative controls for our ChIP 
experiment). 
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and DNA purification, we were able to successfully amplify DNA using Primer pair 1, which 
spans the E2F1 promoter.  There was no amplification product for Primer pair 2 or for Primer 
pair 3, confirming that our reaction conditions did not cause nonspecific binding of Bright to 
chromatin.  With our ChIP protocol optimized, we proceeded to perform a ChIP assay against 
Bright in BTR cells. 
Wild-type Bright infected BTR cells were cross-linked and lysed.  Lysates were 
Figure 11: Bright is recruited to the E2F1 promoter.  Senescence rescue is correlated with 
the loss of HDAC1 at the E2F1 promoter. 
BTR cells were infected with Bright/Arid3a encoding viruses as indicated and grown at the 
permissive temperature for two days, followed by shift to the non-permissive temperature for ten 
days.  PCR and Southern hybridization of immunoprecipitation DNA product is shown in the top 
panel.  Western analysis of the immunoprecipitated DNA-protein complexes is shown in the 
bottom panel.  Bright is found localized at the E2F1 promoter.  At the permissive temperature, 
Bright is found complexed with pRb and HDAC1 at the E2F1 promoter.  At the non-permissive 
temperature, HDAC1 is lost at the E2F1 promoter.    
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sonicated and immunoprecipitation was performed using α-Bright antibody.  A small portion 
of the IP product was analyzed by Western blot.  The remaining sample was reverse cross-
linked, treated with proteinase K and DNA was purified.  DNA was amplified by PCR and 
product was run on a DNA agarose gel followed by transfer to a nitrocellulose membrane and 
southern hybridization using radiolabeled primers.  Signal in lane 4 and 6 of the southern blot 
shows that wild-type Bright is localized to the E2F1 promoter region at both the permissive 
temperature (32°) and the non-permissive temperature (39.5°; Figure 11).  ChIP using α-
preimmune serum served as a negative control confirming specificity of the α-Bright 
antibody.  Primer 2 and Primer 3 produced negative results in the experimental lanes 
supporting the conclusion that Bright is localized to the E2F1 promoter.  This also verifies 
that Bright’s localization on chromatin is not an artifact of the ChIP protocol.  Additionally, 
the positive signal in the input lanes indicates that total chromatin was successfully isolated 
from the BTR cells.  Assuming equal loading, there appears to be more Bright located on the 
E2F1 promoter at 39.5° than 32° in BTR cells.  Western analysis of the immunoprecipitation 
product is shown in Figure 11.  Bright localized to the E2F1 promoter is associated with 
HDAC1 and pRb at the permissive temperature (32°).  However, at the non-permissive 
temperature (39.5°), Bright localized to the E2F1 promoter is associated with pRb only and 
not HDAC1.   
To confirm our results, we performed another ChIP assay using α-HDAC1 antibody 
for the immunoprecipitation step (Figure 12).  Southern hybridization indicates that HDAC1 
can be found at the E2F1 promoter at the permissive temperature (32°) but not at the non-
permissive temperature (39.5°).  The signal in lane 4 of the α-Bright Western confirms that 
Bright is found associated with HDAC1 on the E2F1 promoter at the permissive temperature.  
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The lack of signal in lane 6 of the α-Bright Western supports our earlier result that HDAC1 
does not associate with Bright on chromatin at the non-permissive temperature.   
In both of the ChIP α-Bright Westerns, we noticed signal in Bright negative lanes 
(lanes 1 and 2 of Figure 11; lanes 1 and 2 of Figure 12).  There are two possible origins of 
these signals.  First, they could be the result of nonspecific binding of the α-Bright antibody 
to an unknown protein.  This seems likely since the recognized band runs lower than 74 kDa, 
the size of Bright.  The second possible explanation is that there is endogenous expression of 
Bright in BTR cells.  The Tucker lab has found that Bright expression is not tightly B-cell 
Figure 12: Reciprocal ChIP assay verifies that HDAC1 association with the E2F1 
promoter and Bright is lost during senescence rescue. 
ChIP was performed using α-HDAC1 antibody.  HDAC1 is complexed with Bright and recruited to 
the E2F1 promoter at the permissive temperature (lane 4 bottom panel; lane 4 top panel).  
Consistent with the results of the first ChIP experiment, HDAC1 does not associate with Bright or 
the E2F1 promoter at the non-permissive temperature (lane 6 bottom panel; lane 6 top panel). 
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restricted and there is trace endogenous expression in some cell lines, including fibroblasts.  
Since BTR cells are made from fibroblast cells, these bands could be endogenous Bright.  We 
were unable to further investigate this due to time constraints.   
These results suggest that Bright senescence rescue is correlated with the loss of 
HDAC1 at the E2F1 promoter.  While our ChIP assay has found an association between 
Bright and the E2F1 promoter, we cannot confirm direct binding of Bright to DNA.  EMSA 
assays have the capability of detecting direct binding of proteins to DNA.  Our preliminary 





The goal of this thesis was to investigate the oncogeneic properties of Bright.  First, 
we tested five mutant forms of Bright to determine which ones retained the ability to 
transform cells.  We assayed for both natural senescence rescue and RasV12 senescence 
rescue.  Only wild-type Bright and a sumoylation defective mutant were capable of bypassing 
senescence.  Next, we looked for changes in pRb levels in cells transformed by Bright and 
assayed for an association between Bright and pRb.  Bright immortalization was found to be 
correlated with increased levels of hyperphosphorylated pRb, indicating G1/S progression.  
Additionally, Bright was found to complex predominantly with hyperphosphorylated pRb 
during senescence bypass.  Finally, we used chromatin immunoprecipitation to show that 
Bright is recruited to the E2F1 promoter.  Our results extend the findings of Peeper et al 
(2002) by identifying a potential mechanism for Bright’s oncogenic properties: Bright 
disrupts pRb/E2F1 complexes from repressing transcription of the E2F1 promoter.  As a 
result, E2F1 transcription is de-repressed allowing transcription of genes necessary for G1/S 
cell cycle progression.  While more experiments are needed to clarify the details of our 
proposed model, our results provide a good starting point for future work. 
 Our first aim was to determine which properties of Bright are necessary to transform 
cells.  We conducted cell proliferation assays to determine if various mutant forms of Bright 
could rescue natural senescence in primary MEFs.  We confirmed our results by using 
senescence associated β-galactosidase staining to test for rescue of RasV12 induced 
senescence in BTR cells.  Interestingly, the sumoylation defective mutant, 401KIKK/AIAA, 
rescued senescence along with wild-type Bright.  This suggests that sumoylation is not 
necessary for Bright to function as a proto-oncogene.  All other mutant forms of Bright tested 
did not transform cells.  In the context of our proposed model, it is expected that Bright 
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containing a defective nuclear localization sequence should not rescue senescence.  Without a 
functional NLS, Bright cannot enter the nucleus to de-repress the E2F1 promoter.  But, why 
does the nucleus-restricted Bright mutant (G532A) not rescue senescence?  A likely 
explanation is that the nuclear export sequence mutation makes Bright unable to interact with 
pRb through its ARID domain.  In fact, this is probably why the cysteine substitution mutants 
also did not rescue senescence.  Our immunoprecipitation experiments support this idea since 
these mutant forms of Bright do not associate with pRb (Figure 8).  Overall, it appears that 
Bright must be transcriptionally competent and able to associate with pRb to rescue 
senescence.   
The second phase of this project examined the association between Bright and pRb to 
investigate the possibility that Bright may be involved in pRb-E2F1 regulation.  Western 
analysis showed that Bright immortalization is correlated with the hyperphosphorylation of 
pRb.  This is an indicator of cell proliferation since pRb normally becomes 
hyperphosphorylated by cyclin-dependent kinases during G1/S transition.  Our 
immunoprecipitation assays revealed that Bright predominantly complexes with the 
hyperphosphorylated form of pRb during senescence rescue.  The observation that Bright can 
associate with pRb lends support to our model of senescence bypass.  Bright may associate 
with pRb/E2F1-DP complexes to interfere with their normal repression of the E2F1 
promoter.  This seems likely since our data suggest that Bright is complexed with the pRb 
that is regulating E2F1.   
Our immunoprecipitation assays were unable to confirm direct binding of Bright to 
pRb.  Proteins typically bind to pRb through the LXCXE motif (Dahiya et al, 2000).  
However, many cell cycle regulators, including E2F1, have been shown to bind to the 
COOH-terminal region of pRb.  Bright’s paralogue, Bdp, binds pRb in this fashion via its 
ARID domain (Numata et al, 1999).  The high degree of similarity between Bright and Bdp 
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(89% identical) makes it likely that Bright can also bind pRb via its ARID domain.  Thus, 
mutation of the conserved cysteine (in Bright point mutants C342S and C342D) probably 
results in the inability of the ARID domain to interact with pRb.  It is important to note that 
all the mutants that failed to rescue senescence, including the dominant negative mutant, also 
failed to complex with pRb.  This suggests that association with pRb is essential for Bright to 
function as a proto-oncogene, a conclusion consistent with our model of Bright senescence 
rescue.   
In the last set of experiments, we assayed for an association between Bright and the 
E2F1 promoter.  Unpublished data in the Tucker lab indicated that Bright rescues senescence 
in the same manner as hDril1, downstream of p19ARF, p16INK4a and p53.  Bright 
immortalization also leads to the induction of E2F1 and CYCLIN E, a cell cycle regulator 
whose transcription is activated by E2F1.  Since E2F1 regulation appears to be affected 
during transformation, we hypothesized that Bright may affect the p19ARF/p53 tumor 
suppressor pathway at the level of pRb/E2F1.  Our results are consistent with our hypothesis.  
Bright appears to transform cells by disrupting pRb/E2F1-DP repressive complexes on the 
E2F1 promoter.  This conclusion is based on the observation that HDAC1 is displaced from 
the E2F1 promoter and fails to associate with Bright/pRb complexes during senescence 
rescue (Figures 11 and 12).   
There are several possible mechanisms of Bright’s actions.  One possibility is that 
Bright may sequester hypophosphorylated pRb in the cytoplasm during transformation.  
Presumably, Bright would bind hypophosphorylated pRb and then shuttle to the cytoplasm 
during G1, stopping hypophosphorylated pRb from forming pRb-E2F1 repressive complexes 
in the nucleus.  Consistent with this view is the finding that Bright is predominantly localized 
in the cytoplasm during G1 and shuttles to the nucleus during S phase (Kim and Tucker, 
2006).  Bright shuttling would stop pRb from forming pRb/E2F1-DP repressive complexes in 
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the nucleus.  This model, however, fails to explain our observation that pRb remains 
associated with the E2F1 promoter during senescence rescue (Figure 11, Western lane 6).   
Alternatively, Bright may block the recruitment HDAC1 to the E2F1 promoter.  In 
this mechanism, Bright first associates with hypophosphorylated pRb/E2F1-DP repressive 
complexes.  Next, the Bright/pRb/E2F1-DP complex enters the nucleus and is recruited to the 
E2F1 promoter.  For an unknown reason or by a mechanism yet to be determined, Bright then 
blocks pRb/E2F1-DP complexes from recruiting HDAC1 to the E2F1 promoter.  This 
possibility is supported by our ChIP data showing that during immortalization, Bright and 
pRb maintain association with the E2F1 promoter without the recruitment of HDAC1.  A 
possible signal for Bright to disrupt HDAC1 recruitment could be low levels of nuclear 
E2F1, since senescent cells have low nuclear E2F1 and Bright has been characterized as an 
E2F1 binding protein (Suzuki et al, 1998).   
 While our results help narrow down the general action of Bright, there are several 
lines of future work that should be pursued.  First, more experimentation is needed to 
understand the interaction between Bright and pRb.  Performing in vitro binding assays for 
Bright and pRb may prove insightful.  Additionally, the senescence rescuing ability of Bright 
mutants which are unable to complex/bind to pRb but retain all other functions should be 
examined.  This would help rule out the possibility that Bright’s interaction with pRb is 
unnecessary for senescence rescue.  Another issue worthy of future experimentation is the 
action of Bright at the E2F1 promoter.  Electron mobility shift assays could confirm direct 
binding of Bright to E2F1 promoter DNA.  If Bright does bind directly, then it would be 
valuable to examine the senescence rescuing ability of Bright mutants which are unable to 
bind chromatin but still interact with pRb and E2F1.  Finally, Bright’s potential for tumor 
formation in vivo should be studied.  There may be species specific differences in the ability 
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of Bright vs. hDril1 to form tumors in mice.  Additionally, experiments studying the 




Preparation of MEFs, cell culture and retroviral infection:  Organs and head were removed 
from a 15 day old mouse embryo, and the remaining tissue was washed in phosphate buffered 
saline (PBS) and minced. After a second PBS wash, the tissue was incubated with 100 µl 
trypsin/EDTA (Gibco) on ice for 12 hr. The tissue was incubated with 100 µl trypsin/EDTA 
at 37 °C for 30 min, dissociated in complete medium, and transferred to a 100-mm dish. 
MEFs were maintained in DMEM (Gibco) supplemented with 10% FBS (PAA Laboratories) 
and 0.1 mM β-mercapto ethanol. These MEFs were designated as passage 1 and were 
maintained in the same media.  
Phoenix packaging cells were used to generate ecotropic retroviruses as described 
(Serrano et al., 1997). MEFs were infected with filtered (0.45 µm) viral supernatant, 
supplemented with 4-8 µg/ml polybrene. In general, a single infection round of 6 hrs was 
sufficient to infect at least 90% of the population. 
Btr cells (Peeper et al., 2002) were maintained at 32 ºC and infected using viruses as 
described above.   
 
Proliferation curves:  For proliferation curves, passage 3 MEFs were infected with retroviral 
vectors carrying selectable markers.  At 1-2 days post infection, they were selected with 
puromycin (1-3 µg/ml) for 5-7 days. The number of trypan blue negative cells were counted 
at the indicated time points. 
 
Senescence-associated β-galactosidase staining:  Senescence-associated β -galactosidase 
activity was detected as previously described (Dimri et al., 1995). Cells were washed once 
with PBS (pH 7.2), fixed with 1% glutaraldehyde in PBS (pH 7.2) for 30 min at room 
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temperature, and washed once in PBS (pH 7.2) supplemented with 1mM MgCl2. Cells were 
then stained in X-gal solution (1mg/ml X-gal, 120µM K3Fe[CN]6, 120µM K4Fe[CN]6, 
1mM MgCl2 in PBS at pH 6.0) overnight at 37º C without CO2.  Counterstaining with Eosin 
(Sigma) was performed according to the manufacturer’s instruction.  
 
Western blotting, IP and Chip:  For Western blotting, cell extracts were prepared in NETN 
lysis buffer (100 mM NaCl, 0.5% NP-40, 50 mM TRIS-HCl pH 8.0, 1 mM EDTA, 
supplemented with a protease inhibitor cocktail (Boehringer), assayed for protein 
concentration, and 50-80 µg of clarified extract was resolved on SDS-PAGE gels, followed 
by transfer onto nitrocellulose membranes and probing with antisera, as described in Kim and 
Tucker (2006).  Primary antibodies used for Western blotting were R562 (Abcam) for 
p19ARF, ab9113 (Abcam) for the v5 tag, ab28305 (Abcam) for E1A, 3965 (Cell Signaling) 
for ras, Ab7 (Calbiochem) for p53, and from Santa Cruz: M-156 for p16INK4a, C-19 for 
p21CIP1, M-20 for Cyclin E, C-22 for Cdk4, H-295 for Cyclin D1 and C-22 for actin. Dr. 
Julien Sage, Stanford University, kindly provided the anti-Rb antibody (Sage et al., 2000).  
Affinity-purified, rabbit polyclonal anti-mArid3a generated against full-length bacterially 
synthesized and purified Arid3a has been described (Herrscher et al., 1995). Enhanced 
chemoluminescence (Amersham) was used for detection of proteins. Actin and tubulin served 
as loading controls for all blots.  Chip assays were performed using the Upstate Chip Kit (17-
295) according to the manufacturer’s instructions (Attema et al., 2007).  
 
E2F1 Primer Pair 1: 
Invitrogen 
3’ Primer, Lot# 10336022120836, Sequence: GCTGGAATGGTGTCAGCACAGCG 
5’ Primer, Lot# 10336022120836, Sequence:  TCCAAGAATCATATCCAGTGGCT 
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E2F1 Primer Pair 2: 
Invitrogen 
3’ Primer, Lot# 10336022120836, Sequence:  AACACTTGCTGCCAGGACTT 
5’ Primer, Lot# 10336022120836, Sequence:  TGGCTCACAACCACCTGTAA  
 
E2F1 Primer Pair 3: 
Invitrogen 
3’ Primer, Lot# 10336022120836, Sequence:  GTCCCACCCTCCGTCTCC 
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